肿瘤细胞治疗研究
英文原题：Ten years of translational innovation in HER2-targeted immune cell therapy - A comprehensive review of the work of the University of Debrecen Cell and Molecular Therapy Research Group.
这些努力共同凸显了工程化免疫细胞克服传统疗法关键局限的潜力，并支持 CAR 类方法在实体瘤中的持续演进。
靶向HER2的疗法改善了实体瘤患者结局，但其疗效常受耐药和肿瘤微环境屏障限制。过去十年间，德布勒森大学细胞与分子治疗研究团队致力于开发CAR工程化免疫细胞策略以应对这些挑战。我们的工作涉及CAR-T细胞设计的进展，包括优化共刺激信号、开发模块化靶向系统，并拓展至CAR-NK细胞等现货型平台。总体而言，这些工作凸显工程化免疫细胞克服传统疗法关键局限的潜力，并支持CAR相关实体瘤治疗方法持续演进。
HER2-targeted therapies have improved outcomes in solid tumors, but their efficacy is often limited by resistance and tumor microenvironmental barriers. Over the past decade, the University of Debrecen Cell and Molecular Therapy Research Group has focused on developing CAR-engineered immune cell strategies to address these challenges. Our work spans advances in CAR-T cell design, including optimization of costimulatory signaling, development of modular targeting systems, and expansion toward off-the-shelf platforms such as CAR-NK cells. Collectively, these efforts highlight the potential of engineered immune cells to overcome key limitations of conventional therapies and support the continued evolution of CAR-based approaches for solid tumors. HER2-targeted therapies have improved outcomes in solid tumors, but their efficacy is often limited by resistance and tumor microenvironmental barriers. Over the past decade, the University of Debrecen Cell and Molecular Therapy Research Group has focused on developing CAR-engineered immune cell strategies to address these challenges. Our work spans advances in CAR-T cell design, including optimization of costimulatory signaling, development of modular targeting systems, and expansion toward off-the-shelf platforms such as CAR-NK cells. Collectively, these efforts highlight the potential of engineered immune cells to overcome key limitations of conventional therapies and support the continued evolution of CAR-based approaches for solid tumors.
MEMBER ACCOUNT
登录成功会直接打开下一页。
